Dr. Shahram Mori, MD

Dr. Mori practices at Adventhealth Imaging Medical Plaza Orlando Mri CT - HOPD in Orlando, Florida.

Dr. Mori's NPI, 1891001400, was assigned on August 20, 2010. Dr. Mori holds Nevada license 21041.

Dr. Mori's primary practice is Adventhealth Imaging Medical Plaza Orlando Mri CT - HOPD, at 2501 N Orange Ave, Orlando, FL 32804.

Dr. Mori's primary practice is Adventhealth Imaging Medical Plaza Orlando Mri CT - HOPD in Orlando, Florida. Dr. Mori is also affiliated with AdventHealth Orlando. The medical group on file is AdventHealth Medical Group. Dmand AI also links Dr. Mori to 1 more group practice or clinic, named with a free account. Dr. Mori's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mori practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mori's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Mori's licenses on file in 4 states: Nevada, Arizona, California and Florida.

CMS data shows 394 Medicare services from Dr. Mori across 5 procedure codes in 2024, for 78 Medicare patients. Medicare paid $39,437 for them.

CMS counts 78 Medicare patients who saw Dr. Mori in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mori's median patient age at 68, with 48% women.

In 2024, Dr. Mori wrote 62 Medicare Part D claims for 16 patients. 73% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $77 in total drug cost. In 2023, CMS named 48 claims across 2 drugs.

Dr. Mori accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Mori, published from 2017 to 2024. 2018 was the busiest year, with 8. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Leukemia, Myeloid, Acute. Dr. Mori has published most often in Haematologica. Dr. Mori's most frequent co-authors are Rushang Dilipkumar Patel, MD, PhD, Juan Carlos Varela, MD, PhD and Steven C. Goldstein, MD.

Dmand AI links Dr. Mori to 6 clinical trials, 2 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Anemia, Aplastic and Hepatic Veno-Occlusive Disease. NexImmune Inc. sponsors the most, 2.

CMS Open Payments shows 1,439 general payments to Dr. Mori from 42 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 77% of the total. Incyte Corporation paid the most, $449,140. It also lists 1 research payment totaling $23 in 2020.